Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis [Yahoo! Finance]
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
Arcutis Biotherapeutics announces termination of promotion agreement with Kowa [Yahoo! Finance]
Arcutis Biotherapeutics (NASDAQ:ARQT) had its price target raised by analysts at Needham & Company LLC from $30.00 to $31.00. They now have a "buy" rating on the stock.